FLT3 mutation is the most common RTK mutation in AML, accounting for approximately 30% of cases, of which ITD accounts for approximately 25%, and tyrosine kinase domain (TKD) point mutation accounts for only 7%. This evidence concerns the gene FLT3 and acute myeloid leukemia.